Baillie Gifford & Co’s Precision BioSciences DTIL Stock Holding History

Baillie Gifford & Co’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,025	Closed	-$31.9K	–	294
2023 Q2	$31.9K	Hold	2,025	–	–	﹤0.01%	289
2023 Q1	$45.8K	Sell	2,025 -23	-1%	-$758	﹤0.01%	291
2022 Q4	$73.1K	Hold	2,048	–	–	﹤0.01%	296
2022 Q3	$80K	Buy	2,048 +88	+4%	+$4.18K	﹤0.01%	294
2022 Q2	$94K	Sell	1,960 -92	-4%	-$5.4K	﹤0.01%	298
2022 Q1	$190K	Buy	2,052 +349	+20%	+$47.4K	﹤0.01%	293
2021 Q4	$378K	Buy	1,703 +1,654	+3,376%	+$462K	﹤0.01%	291
2021 Q3	$17K	Buy	49 +21	+75%	+$7.12K	﹤0.01%	388
2021 Q2	$10K	Buy	+28	New	+$8.41K	﹤0.01%	434

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co's DTIL Position: Q3 2023 in Review

Baillie Gifford & Co sold out of Precision BioSciences (DTIL) in Q3 2023, closing a stake of 2,025 shares — an estimated $31.9K sold.

Baillie Gifford & Co first reported a position in DTIL in Q2 2021 and held it in 9 quarters. The position peaked at $378K in Q4 2021. 76 funds tracked by Wall St. Rank hold DTIL as of Q3 2023.

Baillie Gifford & Co reported no remaining Precision BioSciences position as of Q3 2023 after selling out during the quarter.
Baillie Gifford & Co sold 2,025 Precision BioSciences shares in Q3 2023, an estimated $31.9K.
Baillie Gifford & Co first reported a position in Precision BioSciences in Q2 2021 and held it in 9 quarters.
Baillie Gifford & Co's Precision BioSciences position peaked at $378K in Q4 2021.
76 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2023.

Based on Baillie Gifford & Co's 13F filing for Q3 2023, filed 13 Nov 2023.